144 related articles for article (PubMed ID: 33849962)
1. Targeted Deep Sequencing of Bladder Tumors Reveals Novel Associations between Cancer Gene Mutations and Mutational Signatures with Major Risk Factors.
Koutros S; Rao N; Moore LE; Nickerson ML; Lee D; Zhu B; Pardo LA; Baris D; Schwenn M; Johnson A; Jones K; Garcia-Closas M; Prokunina-Olsson L; Silverman DT; Rothman N; Dean M
Clin Cancer Res; 2021 Jul; 27(13):3725-3733. PubMed ID: 33849962
[TBL] [Abstract][Full Text] [Related]
2. Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer.
Bellmunt J; Kim J; Reardon B; Perera-Bel J; Orsola A; Rodriguez-Vida A; Wankowicz SA; Bowden M; Barletta JA; Morote J; de Torres I; Juanpere N; Lloreta-Trull J; Hernandez S; Mouw KW; Taplin ME; Cejas P; Long HW; Van Allen EM; Getz G; Kwiatkowski DJ
Cancer Res; 2020 Oct; 80(20):4476-4486. PubMed ID: 32868381
[TBL] [Abstract][Full Text] [Related]
3. Procarcinogen Activation and Mutational Signatures Model the Initiation of Carcinogenesis in Human Urothelial Tissues In Vitro.
Baker SC; Mason AS; Southgate J
Eur Urol; 2020 Aug; 78(2):143-147. PubMed ID: 32349929
[TBL] [Abstract][Full Text] [Related]
4. Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival.
Yap KL; Kiyotani K; Tamura K; Antic T; Jang M; Montoya M; Campanile A; Yew PY; Ganshert C; Fujioka T; Steinberg GD; O'Donnell PH; Nakamura Y
Clin Cancer Res; 2014 Dec; 20(24):6605-17. PubMed ID: 25316812
[TBL] [Abstract][Full Text] [Related]
5. Molecular footprints of muscle-invasive bladder cancer in smoking and nonsmoking patients.
Fantini D; Seiler R; Meeks JJ
Urol Oncol; 2019 Nov; 37(11):818-825. PubMed ID: 30446446
[TBL] [Abstract][Full Text] [Related]
6. Nitrated Polycyclic Aromatic Hydrocarbon (Nitro-PAH) Signatures and Somatic Mutations in Diesel Exhaust-Exposed Bladder Tumors.
Gonzalez N; Rao N; Dean M; Lee D; Hurson AN; Baris D; Schwenn M; Johnson A; Prokunina-Olsson L; Friesen MC; Zhu B; Rothman N; Silverman DT; Koutros S
Cancer Epidemiol Biomarkers Prev; 2023 Jun; 32(6):840-847. PubMed ID: 36996403
[TBL] [Abstract][Full Text] [Related]
7. Extensive heterogeneity in somatic mutation and selection in the human bladder.
Lawson ARJ; Abascal F; Coorens THH; Hooks Y; O'Neill L; Latimer C; Raine K; Sanders MA; Warren AY; Mahbubani KTA; Bareham B; Butler TM; Harvey LMR; Cagan A; Menzies A; Moore L; Colquhoun AJ; Turner W; Thomas B; Gnanapragasam V; Williams N; Rassl DM; Vöhringer H; Zumalave S; Nangalia J; Tubío JMC; Gerstung M; Saeb-Parsy K; Stratton MR; Campbell PJ; Mitchell TJ; Martincorena I
Science; 2020 Oct; 370(6512):75-82. PubMed ID: 33004514
[TBL] [Abstract][Full Text] [Related]
8. A case-control study of smoking and bladder cancer risk: emergent patterns over time.
Baris D; Karagas MR; Verrill C; Johnson A; Andrew AS; Marsit CJ; Schwenn M; Colt JS; Cherala S; Samanic C; Waddell R; Cantor KP; Schned A; Rothman N; Lubin J; Fraumeni JF; Hoover RN; Kelsey KT; Silverman DT
J Natl Cancer Inst; 2009 Nov; 101(22):1553-61. PubMed ID: 19917915
[TBL] [Abstract][Full Text] [Related]
9. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors.
Kim J; Mouw KW; Polak P; Braunstein LZ; Kamburov A; Kwiatkowski DJ; Rosenberg JE; Van Allen EM; D'Andrea A; Getz G
Nat Genet; 2016 Jun; 48(6):600-606. PubMed ID: 27111033
[TBL] [Abstract][Full Text] [Related]
10. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy.
Mossanen M; Carvalho FLF; Muralidhar V; Preston MA; Reardon B; Conway JR; Curran C; Freeman D; Sha S; Sonpavde G; Hirsch M; Kibel AS; Van Allen EM; Mouw KW
Eur Urol; 2022 May; 81(5):466-473. PubMed ID: 34953602
[TBL] [Abstract][Full Text] [Related]
11. Analysis of Several Common APOBEC-type Mutations in Bladder Tumors Suggests Links to Viral Infection.
Rao N; Starrett GJ; Piaskowski ML; Butler KE; Golubeva Y; Yan W; Lawrence SM; Dean M; Garcia-Closas M; Baris D; Johnson A; Schwenn M; Malats N; Real FX; Kogevinas M; Rothman N; Silverman DT; Dyrskjøt L; Buck CB; Koutros S; Prokunina-Olsson L
Cancer Prev Res (Phila); 2023 Oct; 16(10):561-570. PubMed ID: 37477495
[TBL] [Abstract][Full Text] [Related]
12. Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing.
Wang F; Dong X; Yang F; Xing N
Front Genet; 2022; 13():831146. PubMed ID: 35419031
[No Abstract] [Full Text] [Related]
13. Potential effect modifiers of the arsenic-bladder cancer risk relationship.
Koutros S; Baris D; Waddell R; Beane Freeman LE; Colt JS; Schwenn M; Johnson A; Ward MH; Hosain GM; Moore LE; Stolzenberg-Solomon R; Rothman N; Karagas MR; Silverman DT
Int J Cancer; 2018 Dec; 143(11):2640-2646. PubMed ID: 29981168
[TBL] [Abstract][Full Text] [Related]
14. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.
Wallerand H; Bakkar AA; de Medina SG; Pairon JC; Yang YC; Vordos D; Bittard H; Fauconnet S; Kouyoumdjian JC; Jaurand MC; Zhang ZF; Radvanyi F; Thiery JP; Chopin DK
Carcinogenesis; 2005 Jan; 26(1):177-84. PubMed ID: 15347601
[TBL] [Abstract][Full Text] [Related]
15. Mutational spectra and mutational signatures: Insights into cancer aetiology and mechanisms of DNA damage and repair.
Phillips DH
DNA Repair (Amst); 2018 Nov; 71():6-11. PubMed ID: 30236628
[TBL] [Abstract][Full Text] [Related]
16. Occupational exposure to pesticides and bladder cancer risk.
Koutros S; Silverman DT; Alavanja MC; Andreotti G; Lerro CC; Heltshe S; Lynch CF; Sandler DP; Blair A; Beane Freeman LE
Int J Epidemiol; 2016 Jun; 45(3):792-805. PubMed ID: 26411407
[TBL] [Abstract][Full Text] [Related]
17. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes.
Wu X; Gu J; Grossman HB; Amos CI; Etzel C; Huang M; Zhang Q; Millikan RE; Lerner S; Dinney CP; Spitz MR
Am J Hum Genet; 2006 Mar; 78(3):464-79. PubMed ID: 16465622
[TBL] [Abstract][Full Text] [Related]
18. Elevated APOBEC mutational signatures implicate chronic injury in etiology of an aggressive head-and-neck squamous cell carcinoma: a case report.
Patel J; den Breems NY; Tuluc M; Johnson J; Curry JM; South AP; Cho RJ
J Med Case Rep; 2021 Apr; 15(1):252. PubMed ID: 33926553
[TBL] [Abstract][Full Text] [Related]
19. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer.
Shi MJ; Meng XY; Fontugne J; Chen CL; Radvanyi F; Bernard-Pierrot I
Genome Med; 2020 Sep; 12(1):85. PubMed ID: 32988402
[TBL] [Abstract][Full Text] [Related]
20. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
